Patients with ALK-positive NSCLC feature a more advanced stage and have a higher risk of developing brain metastases than patients with other NSCLC sub-types, thus having a lower quality of life and a poorer prognosis [4]. This evidence concerns the gene ALK and non-small cell lung carcinoma.